Duloxetine News and Research

RSS
Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.
AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Depression drug appears effective in reducing pain associated with breast cancer treatment

Depression drug appears effective in reducing pain associated with breast cancer treatment

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

FDA grants Impax tentative approval for generic Cymbalta NDA

FDA grants Impax tentative approval for generic Cymbalta NDA

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Survey shows only few Canadians identify painful physical symptoms of depression

Survey shows only few Canadians identify painful physical symptoms of depression

Combination therapy for severe depression

Combination therapy for severe depression

Treatment options available for GAD

Treatment options available for GAD

Study shows Cymbalta reduces chronic low back pain

Study shows Cymbalta reduces chronic low back pain

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

FDA approves once-daily SEROQUEL XR Extended Release Tablets

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Eli Lilly's Cymbalta receives FDA approval

Eli Lilly's Cymbalta receives FDA approval

Positive results from Winston Laboratories' Civamide Patch trial

Positive results from Winston Laboratories' Civamide Patch trial

New systematic study for managing treatment-resistant bipolar depression

New systematic study for managing treatment-resistant bipolar depression

Cymbalta maintains reduction in pain for patients with chronic low back pain

Cymbalta maintains reduction in pain for patients with chronic low back pain

Merck update on the status of telcagepant clinical development programs

Merck update on the status of telcagepant clinical development programs

Venlafaxine alleviates depressive symptoms

Venlafaxine alleviates depressive symptoms

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

New antidepressants might be no more effective than the best existing drugs

New antidepressants might be no more effective than the best existing drugs